Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Caputo

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Cancer Treatment Reviews|January 11, 2025
CAR-T cell therapy for breast cancer: Current status and future perspectiveGiuseppe Buono, Monica Capozzi, Roberta Caputo, et al.
Breast (Edinburgh, Scotland)|November 23, 2024
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysisRoberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, et al.
International Journal of Molecular Sciences|September 9, 2020
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-AnalysisMichela Piezzo, Paolo Chiodini, Maria Riemma, et al.
The Breast Journal|July 25, 2019
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analoguesAlessandro Conforti, Francesco Schettini, Roberta Vallone, et al.
BMC Cancer|March 20, 2020
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II studyRoberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, et al.
The Oncologist|July 1, 2025
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)Carmine De Angelis, Martina Pagliuca, Emanuela Magnolfi, et al.
Breast (Edinburgh, Scotland)|March 17, 2024
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patientsFederica Miglietta, Letizia Pontolillo, Carmine De Angelis, et al.
Targeted Oncology|September 24, 2022
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 StudyMichelino De Laurentiis, Roberta Caputo, Manuelita Mazza, et al.
Journal of the National Cancer Institute|February 5, 2025
Prognostic implications of risk definitions from the monarchE and NATALEE trialsLuca Arecco, Eva Blondeaux, Marco Bruzzone, et al.
Breast (Edinburgh, Scotland)|December 30, 2017
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Mario Giuliano, Francesco Schettini, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Cancer Treatment Reviews|January 11, 2025
CAR-T cell therapy for breast cancer: Current status and future perspectiveGiuseppe Buono, Monica Capozzi, Roberta Caputo, et al.
Breast (Edinburgh, Scotland)|November 23, 2024
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysisRoberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, et al.
International Journal of Molecular Sciences|September 9, 2020
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-AnalysisMichela Piezzo, Paolo Chiodini, Maria Riemma, et al.
The Breast Journal|July 25, 2019
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analoguesAlessandro Conforti, Francesco Schettini, Roberta Vallone, et al.
BMC Cancer|March 20, 2020
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II studyRoberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, et al.
The Oncologist|July 1, 2025
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)Carmine De Angelis, Martina Pagliuca, Emanuela Magnolfi, et al.
Breast (Edinburgh, Scotland)|March 17, 2024
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patientsFederica Miglietta, Letizia Pontolillo, Carmine De Angelis, et al.
Targeted Oncology|September 24, 2022
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 StudyMichelino De Laurentiis, Roberta Caputo, Manuelita Mazza, et al.
Journal of the National Cancer Institute|February 5, 2025
Prognostic implications of risk definitions from the monarchE and NATALEE trialsLuca Arecco, Eva Blondeaux, Marco Bruzzone, et al.
Breast (Edinburgh, Scotland)|December 30, 2017
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Mario Giuliano, Francesco Schettini, et al.
Pageof 5